BPC-157is the default internet answer to every gym injury that won’t heal. That reputation is earned — but it’s the entry point, not the full picture. TB-500 handles cell migration and structural tissue rebuilding through a different pathway. KPV brings the anti-inflammatory and gut-microbiome layer that neither of the others covers. KLOWis the pre-blended option that combines all four recovery peptides — plus GHK-Cu for collagen synthesis — in a single vial.
This post covers how each compound works, how they fit together, and when to run the full stack versus starting with one.
The lineup
- BPC-157— 15-amino-acid partial sequence of body protection compound; promotes angiogenesis and wound healing in tendons, ligaments, muscle, and gut; upregulates growth hormone receptor density in tendon fibroblasts; orally bioavailable
- TB-500— partial sequence of thymosin beta-4, the actin-binding domain; promotes cell proliferation, cell migration, angiogenesis, and antifibrotic effects (scar tissue reduction); produced naturally by the thymus gland during puberty, declining with age
- KPV— tripeptide derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone; anti-inflammatory, antimicrobial, and antifungal; supports butyrate production and gut microbiome rebalancing; orally bioavailable
- KLOW— pre-blended vial of GHK-Cu, BPC-157, TB-500, and KPV; GHK-Cu is the primary active component driving collagen synthesis; the blend covers the full recovery stack in a single vial
BPC-157: what it actually does
BPC-157 is a synthetic 15-amino-acid peptide — a partial sequence of a protein found in human gastric juice, discovered by Dr. Predrag Sikiric in Croatia in 1993. The scientific literature on it runs to roughly 180 animal studies, almost all in rat models. There is one abandoned human clinical trial with unpublished results, and one retrospective human study on intraarticular knee injections that showed improvement in 87.5% of patients. That’s the human evidence base: small, not controlled, but directionally consistent.
The core mechanism is angiogenesis (new blood vessel formation) and wound healing across soft tissue — tendons, ligaments, muscle, gut lining. One effect that matters for stack design: BPC-157 upregulates growth hormone receptor expression in tendon fibroblasts, which creates a synergistic effect with exogenous GH when both are used during an injury protocol. Unlike most peptides, BPC-157 is orally bioavailable because it’s a fragment of a bioidentical compound found in the intestinal tract — useful for gut repair without injection.
One thing BPC-157 does not do: prevent connective tissue injuries pre-emptively. The animal evidence shows it heals tissue after damage, not before. And if you have a structurally torn tendon, surgery comes first — no peptide will reattach separated tissue. The protocol starts after the structural repair is done.
Dosing for soft tissue: 200–1000 mcg per day, split into two injections, subcutaneous or intramuscular, as close to the injury site as practical. The short half-life (estimated 15–30 minutes intramuscularly) is the reason for splitting the dose. For gut healing: 250–500 mcg oral once or twice daily until symptoms resolve. For the full breakdown — mechanism, dosing tiers, the human-vs-rat data caveats — see the dedicated BPC-157 post.
TB-500: the structural rebuilder
TB-500 is the actin-binding domain (amino acids 17–23) of thymosin beta-4. All major claims about its healing properties are extrapolated from thymosin beta-4, which has over a thousand studies; TB-500 itself has five published studies and no completed clinical trials. That evidence gap is real — but the mechanistic rationale is strong enough that it has become the standard pairing with BPC-157 in recovery protocols.
Where BPC-157 drives angiogenesis and GH receptor expression, TB-500 drives cell proliferation, cell migration, and antifibrotic effects — organizing and rebuilding tissue structure while reducing scar formation that slows functional recovery. It also lowers systemic inflammation through purinergic receptors.
Dosing: 500 mcg to 1 mg per day, subcutaneous or intramuscular, as close to the injury site as practical. Once-daily dosing is the standard protocol — TB-500’s active life in plasma is substantially longer than BPC-157’s, supporting a simpler dosing cadence. Rotate injection sites in a clock-face pattern around the injury to prevent thickening at a single spot. One pharmacological note: DPP-4 enzymes metabolize TB-500 in plasma; inhibiting DPP-4 prolongs its active life and extends the detection window for drug-tested athletes.
KPV: the anti-inflammatory layer
KPV (Lys-Pro-Val) is a tripeptide derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone. It carries the parent peptide’s anti-inflammatory and antimicrobial properties without any melanogenic effect. Two situations make it most relevant.
The first is gut healing. KPV has antimicrobial and antifungal properties useful against candida overgrowth and post-antibiotic dysbiosis, supports butyrate production, and preserves beneficial gut flora. Pairing 500 mcg oral KPV with 500 mcg oral BPC-157 addresses both structural lining repair and the microbial environment simultaneously. Larazotide (250 mg twice daily) is sometimes added to this gut stack specifically for tight-junction repair — intestinal barrier tightening that BPC-157 and KPV do not directly address.
The second is systemic anti-inflammatory coverage in an injury protocol. Elevated CRP (above 3) is the clearest indicator that this layer is relevant. Chronic inflammation slows collagen deposition; KPV controls that environment while BPC-157 and TB-500 handle the tissue mechanics.
Dosing: 100–1000 mcg per day, oral or subcutaneous depending on the target. Injection-site redness is more prominent with KPV than with most other peptides; rotate sites. KPV landed on the FDA Section 503a restricted list in October 2023 alongside BPC-157.
KLOW: the all-in-one option
KLOW bundles GHK-Cu, BPC-157, TB-500, and KPV into a single vial. GHK-Cu — glycyl-l-histidyl-l-lysine copper, a bioidentical copper-binding peptide the body produces naturally — is the primary active component and the basis for dosing. BPC-157 adds GH receptor upregulation; TB-500 adds cell migration and antifibrotic support; KPV adds the anti-inflammatory layer. Reconstitute the 80 mg vial with 2 mL BAC water for 40 mg/mL, then use the KLOW calculator for the exact draw.
The case for KLOW is simplicity: one injection covers the full stack. The trade-off is fixed ratios. If you want to cycle BPC-157 while keeping GHK-Cu running continuously — or dial in TB-500 dosing independently — separate vials give that control. For most people starting a recovery protocol, KLOW is the less complicated path to the same destination. Supplement with 25 mg zinc picolinate throughout the run — the GHK-Cu component carries copper, and the two compete for the same binding proteins.
How they stack
BPC-157 and TB-500 are the canonical pairing because they work on different cellular targets: BPC-157 drives angiogenesis, GH receptor upregulation in tendon fibroblasts, and wound surface healing; TB-500 drives cell migration, tissue organization, and antifibrotic remodeling.
Administer them at separate times of day. Both promote angiogenesis, and staggering prevents redundant signaling at the same receptor systems. A practical split: TB-500 near the injury in the morning, BPC-157 near the injury in the afternoon.
KPV adds the third layer when systemic inflammation is elevated or gut healing is part of the picture — cytokine activity and microbial balance, which neither BPC-157 nor TB-500 addresses directly. GHK-Cu, if present via KLOW or standalone, shifts role from active repair to maintenance collagen synthesis once the injury resolves and can continue long-term.
Cycling and timing
Injectable BPC-157 and TB-500 are both typically run for four to eight weeks per injury course — BPC-157 on the shorter end (four to six weeks), TB-500 through the full healing window. Tissue continues improving for weeks after the course ends. KPV matches the same window in an injury protocol; for standalone gut healing, continue until symptoms resolve.
The phase-out signal is functional: when the injury is healed and rehab begins, BPC-157 and TB-500 come out. Continuous angiogenesis without a repair target is unnecessary. GHK-Cu is bioidentical and suitable for ongoing use after the injury course ends. For KLOW run specifically for anti-aging or skin goals, three to six months minimum is the appropriate frame rather than the injury-course window.
The bottom line
For a single stubborn soft-tissue injury, BPC-157 is the reasonable starting point — the evidence base is the largest of the four and the protocol is straightforward. Add TB-500 at a separate injection time when the injury is persistent or complex. Bring KPV in when gut symptoms or elevated systemic inflammation are part of the picture. Run KLOW when you want all four peptides without four separate sourcing decisions.
For reconstitution math, use the BPC-157 calculator and the KLOW calculator. For complete dosing protocols, timing schedules, and cycle guidance, the free Peptide Guide has the full recovery stack from start to finish.